- Home
- RNA
as 01-17-2025 4:00pm EST
Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 4.4B | IPO Year: | 2020 |
| Target Price: | $65.80 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.85 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.93 - $56.00 | Next Earning Date: | 02-26-2025 |
| Revenue: | $10,117,000 | Revenue Growth: | -0.19% |
| Revenue Growth (this year): | -8.29% | Revenue Growth (next year): | -18.14% |
Stock Insider Trading Activity of Avidity Biosciences Inc. (RNA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Boyce Sarah | RNA | President and CEO | Dec 18 '24 | Sell | $32.66 | 31,855 | $1,040,384.30 | 265,308 | |
| MacLean Michael F | RNA | Chief Financial Officer | Dec 18 '24 | Sell | $32.66 | 11,151 | $364,191.66 | 82,942 | |
| Flanagan W. Michael | RNA | CSTO | Dec 18 '24 | Sell | $32.66 | 12,742 | $416,153.72 | 72,647 | |
| McCarthy Teresa | RNA | Chief Human Resources Officer | Dec 18 '24 | Sell | $32.66 | 11,151 | $364,191.66 | 82,867 | |
| McCarthy Teresa | RNA | Chief Human Resources Officer | Dec 16 '24 | Sell | $33.26 | 25,000 | $831,605.00 | 82,867 | |
| Flanagan W. Michael | RNA | CSTO | Dec 11 '24 | Sell | $35.77 | 24,000 | $858,400.80 | 72,647 | |
| LEVIN ARTHUR A | RNA | Director | Nov 19 '24 | Sell | $42.12 | 3,323 | $139,972.74 | 14,830 | |
| McCarthy Teresa | RNA | Chief Human Resources Officer | Nov 18 '24 | Sell | $41.14 | 25,000 | $1,028,520.00 | 82,867 | |
| MacLean Michael F | RNA | Chief Financial Officer | Nov 6 '24 | Sell | $45.63 | 106,319 | $4,843,979.06 | 82,942 | |
| LEVIN ARTHUR A | RNA | Director | Oct 21 '24 | Sell | $46.63 | 5,000 | $233,167.50 | 14,830 |
Latest Avidity Biosciences Inc. News
RNA Breaking Stock News: Dive into RNA Ticker-Specific Updates for Smart Investing
PR Newswire
11 days ago
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
11 days ago
Avidity Biosciences Plans to Submit First Biologics License Application This Year
PR Newswire
11 days ago
Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025
Insider Monkey
18 days ago
Why Is Avidity Biosciences, Inc. (RNA) Among the Best Multibagger Stocks to Buy Right Now?
PR Newswire
a month ago
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
a month ago
HC Wainwright Initiates Coverage on Avidity Biosciences With Buy Rating, $72 Price Target
MT Newswires
a month ago
Avidity Biosciences Insider Sold Shares Worth $1,040,384, According to a Recent SEC Filing
MT Newswires
a month ago
Avidity Biosciences Insider Sold Shares Worth $831,605, According to a Recent SEC Filing
Compare RNA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RNA Avidity Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.